KRAS and colorectal cancer: At present, however, only an arbitrary section of the primary tumor is analyzed for KRAS mutations in colorectal cancer patients and the genomic heterogeneity of metastatic cells—the actual targets of systemic therapy–is not taken into consideration for therapy decisions.